Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11345681 Inhibitors of fibroblast growth factor receptor kinases

Patent 11345681 was granted and assigned to Kinnate Biopharma Inc. on May, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Kinnate Biopharma Inc.

0

Current Assignee

Kinnate Biopharma Inc.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Toufike Kanouni0

Lee D. Arnold0

Robert Kania0

Stephen W. Kaldor0

Eric A. Murphy0

Jason M. Cox0

John Tyhonas0

Date of Patent

May 31, 2022

0

Patent Application Number

173391230

Date Filed

June 4, 2021

0

Patent Citations

US Patent 10588907 Methods and compositions for inhibiting the interaction of menin with MLL proteins

US Patent 10450303 Biaryl piperidine amide compounds and methods of use thereof

US Patent 10077271 Methods and compositions for inhibiting the interaction of menin with MLL proteins

US Patent 10174041 Methods and compositions for inhibiting the interaction of menin with MLL proteins

US Patent 10206931 Therapeutic compounds and uses thereof

US Patent 10239861 Therapeutic compounds and uses thereof

US Patent 10377743 Inhibitors of RAS and methods of use thereof

Patent Primary Examiner

0

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11345681 Inhibitors of fibroblast growth factor receptor kinases

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool